| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 02/10/2005 | US20050031772 Ginger extract preparation |
| 02/10/2005 | US20050031605 Compositions and methods of treating diabetes |
| 02/10/2005 | US20050031603 Obtainable from whey fraction of milk curd; centrifugation; ultrafiltration; lyophilization |
| 02/10/2005 | US20050031601 Composition comprising a lactobacillus pentosus strain and uses thereof |
| 02/10/2005 | US20050031583 Uses of opg to modulate immune responses |
| 02/10/2005 | US20050029705 Extrusion die |
| 02/10/2005 | DE19845403B4 Mit Gallensäuren verknüpfte Propanolaminderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung With bile acids linked Propanolaminderivate, processes for their preparation, pharmaceutical compositions containing them and their use |
| 02/10/2005 | CA2769570A1 Calcium carbonate granulation |
| 02/10/2005 | CA2716449A1 Calcium carbonate granulation |
| 02/10/2005 | CA2534473A1 Substituted benzoylureido-o-benzoylamides, method for the production thereof and use of the same |
| 02/10/2005 | CA2534464A1 Benzoxazepine compound |
| 02/10/2005 | CA2534309A1 Method of evaluating compound efficacious in treating obesity by using slc25a10 |
| 02/10/2005 | CA2533901A1 Piperazine derivatives and their use as therapeutic agents |
| 02/10/2005 | CA2533900A1 Pyridyl derivatives and their use as therapeutic agents |
| 02/10/2005 | CA2533898A1 Pyridyl derivatives and their use as therapeutic agents |
| 02/10/2005 | CA2533897A1 Pyridazine derivatives and their use as therapeutic agents |
| 02/10/2005 | CA2533893A1 Hexahydrodiazepinones as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| 02/10/2005 | CA2533673A1 Substituted thiazole-benzoisothiazole dioxide derivatives, method for the production thereof and use of the same |
| 02/10/2005 | CA2531333A1 Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors |
| 02/10/2005 | CA2531294A1 2-methylene-19-nor-20(s)-25-methyl-1.alpha.-hydroxycalciferol and its uses |
| 02/10/2005 | CA2529662A1 Aryl dicarboxamides |
| 02/10/2005 | CA2528834A1 5-substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the nicotinic acid receptor rup25 for the treatment of dyslipidemia and related diseases |
| 02/10/2005 | CA2527861A1 Alkynyl aryl carboxamides |
| 02/10/2005 | CA2526589A1 Processed fat composition for preventing/ameliorating lifestyle-related diseases |
| 02/09/2005 | EP1505075A1 Antibody to human insulin-like growth factor |
| 02/09/2005 | EP1505074A1 Histamine receptor h3 ordinary activity mutant and utilization thereof |
| 02/09/2005 | EP1505063A1 Benzimidazole derivatives |
| 02/09/2005 | EP1504778A2 Implantable pump for the treatment of obesity |
| 02/09/2005 | EP1504761A1 Difructose anhydride-containing composition and use thereof |
| 02/09/2005 | EP1504124A1 Ldl receptor-related proteins 1 and 2 and treatment of bone or cartilage conditions |
| 02/09/2005 | EP1503996A1 Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors |
| 02/09/2005 | EP1503991A1 Hexahydro-pyridazine-3-carboxylic acid derivatives, pharmaceutical compositions containing same and preparation methods thereof |
| 02/09/2005 | EP1503989A1 Dopamine receptor modulators as antipsychotic agents |
| 02/09/2005 | EP1503781A1 Treatment for weight loss |
| 02/09/2005 | EP1503779A2 Methods for slowing senescence and treating and preventing diseases associated with senescence |
| 02/09/2005 | EP1503778A2 Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent |
| 02/09/2005 | EP1503777A1 7-hydroxy chromones as potent antioxidants |
| 02/09/2005 | EP1503773A1 Hepatoprotective activity of 2 -p-hydroxybenzoylmussaenosidic acid |
| 02/09/2005 | EP1503772A1 Soluble composition containing sporopollenin and the use thereof |
| 02/09/2005 | EP1503767A2 Compositions and methods for treatment of vitamin d deficiency |
| 02/09/2005 | EP1503761A1 Substituted piperazines as melanocortin receptor ligands |
| 02/09/2005 | EP1503755A1 Zonisamide use in obesity and eating disorders |
| 02/09/2005 | EP1503749A2 Methionine aminopeptidase-2 inhibitors and methods of use thereof |
| 02/09/2005 | EP1503740A1 Monocompartment osmotic controlled drug delivery system |
| 02/09/2005 | EP1432436A4 Nutrient therapy for immuno-compromised patients |
| 02/09/2005 | EP1423132A4 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2 |
| 02/09/2005 | EP1420802A4 Increased solubility flavanolignan preparations |
| 02/09/2005 | EP1392285B1 Medicament containing an effector of the glutathione metabolism together with alpha-lipoic acid for use in kidney replacement therapy |
| 02/09/2005 | EP1242121B1 Polypeptide compositions with improved stability |
| 02/09/2005 | EP1235799B1 Polymorphic form of atorvastatin calcium |
| 02/09/2005 | EP1223927B1 Use of retigabin for treating neuropathic pain |
| 02/09/2005 | EP1200076A4 Calcilytic compounds |
| 02/09/2005 | EP1184366B1 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha(ppar) |
| 02/09/2005 | EP1150960B1 Polymorphic crystalline forms of celecoxib |
| 02/09/2005 | EP1140939B1 Substituted 2-aryl-3-(heteroaryl)-imidazo[1,2-alpha]pyrimidines, and related pharmaceutical compositions and methods |
| 02/09/2005 | EP1098639B1 Use of the glucose uptake enhancer rosiglitazone for reducing ischaemia-induced apoptosis of pancreatic beta cells, endothelial cells and neuronal cells |
| 02/09/2005 | EP1042316B1 Indole derivatives useful a.o. for the treatment of osteoporosis |
| 02/09/2005 | CN1578782A Silicon compounds |
| 02/09/2005 | CN1578781A 1, 8 naphthyridine derivatives and their use to treat diabetes and related disorders |
| 02/09/2005 | CN1578780A 1, 6-naphthyridine derivatives as antidiabetics and pharmaceutical compositions containing them |
| 02/09/2005 | CN1578772A Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist |
| 02/09/2005 | CN1578768A Anthranilic acid amides and pharmaceutical use thereof |
| 02/09/2005 | CN1578767A Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient |
| 02/09/2005 | CN1578669A Compositions and methods for treating subjects with hyperglycemia |
| 02/09/2005 | CN1578665A Type 4 phosphodiesterase inhibitors and uses thereof |
| 02/09/2005 | CN1578661A Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors |
| 02/09/2005 | CN1578659A Modulators of peroxisome proliferator activated receptors (ppar) |
| 02/09/2005 | CN1575809A Antilipemic Chinese herbal medicine |
| 02/09/2005 | CN1575803A Application method of Aloe vera L. extract in preventing and curing diabetes |
| 02/09/2005 | CN1575802A Composition for suppressing blood sugar ascending |
| 02/09/2005 | CN1575800A Application of astragalus root polysaccharide in preparation of antilipemic agent and health products |
| 02/09/2005 | CN1575799A Application of Artemisia sphaerocephala Krasch polysaccharide in prrparation of antilipemic agent and health products |
| 02/09/2005 | CN1575793A Functional chewing gum composition for improving effectively obesity and blood fat |
| 02/09/2005 | CN1188426C Antibodise against phosphorylated VASP (vasodilator-stimulated phosphoprotein), hybridoma cells for their preparation, and their use |
| 02/09/2005 | CN1188405C New Morpholinobenzamide salts |
| 02/09/2005 | CN1188403C Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 02/09/2005 | CN1188150C Hypoglycemic liquid its prep. |
| 02/09/2005 | CN1188121C Therapeutic substituted guanidines |
| 02/09/2005 | CN1188120C Method for treating eating disorders |
| 02/09/2005 | CN1188111C Dry powder compositions having improved dispersivity |
| 02/08/2005 | US6852753 Treating hyperlipidemic condition, gallstones |
| 02/08/2005 | US6852749 Pyrazolidinol compounds |
| 02/08/2005 | US6852738 Potent ligands for PPAR gamma and generally have antagonist or partial agonist activity. The compoundsare for treatment, control or prevention of obesity, non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, |
| 02/08/2005 | US6852736 Phenoxypropanolamines, preparation and therapeutic use thereof |
| 02/08/2005 | US6852735 Novel siastatin B derivative having a potent inhibitory activity against a glycosidase, are now synthesized by new processes. The a potent enzyme inhibitory activity to a glycosidase, which is particularly N- |
| 02/08/2005 | US6852727 Inhibitors of Janus protein tyrosine kinases (Jak), and as such are useful as immunosuppressants, and in the treatment of diseases including asthma, allergies, autoimmune diseases. |
| 02/08/2005 | US6852725 Imidazolyl derivatives |
| 02/08/2005 | US6852719 Glucocorticoid receptor modulators |
| 02/08/2005 | US6852717 Inhibit the release of inflammatory cytokines such as interleukin-1 and tumor necrosis factor; for use in therapy of diseases and pathological conditions involving inflammation such as chronic inflammatory disease |
| 02/08/2005 | US6852707 Using xylobiose or xylooligosaccharide containing xylobiose as a main ingredient in place of lactulose, there is provided a blood ammonia lowering agent, a therapeutic agent of hyperammonemia or a therapeutic agent of hepatic |
| 02/08/2005 | US6852701 Sulfamate compound |
| 02/08/2005 | US6852695 For therapy of hyperglycemic disorders |
| 02/08/2005 | US6852693 Compositions and methods for promoting lipid mobilization in humans |
| 02/08/2005 | US6852520 DSP-2 dual-specificity phosphatase |
| 02/08/2005 | US6852518 Glycosyl sulfotransferases GST-4α, GST-4β, and GST-6 |
| 02/08/2005 | US6852343 Antiadipose topical treatment composition based on garlic bulbs extracts, and cosmetic and therapeutic uses |
| 02/08/2005 | US6852335 Folic acid in solid dosage forms |
| 02/08/2005 | CA2287316C Process for preparing 6-o-monoesters of castanospermine |
| 02/08/2005 | CA2180103C Gene encoding adseverin |
| 02/06/2005 | CA2476801A1 Method and apparatus for the treatment of obesity |